Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MIF | P14174 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 5/20 | 0.59 |
| ▸ | PPARD | Q03181 | 5/20 | 0.59 |
| ▸ | PPARA | Q07869 | 5/20 | 0.59 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.58 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.58 |
| ▸ | ALB | P02768 | 2/20 | 0.57 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098366 | 0.94 | MEN1 (0.67) | MEN1KMT2APPARGPPARDPPARA | |
| SCHEMBL4100942 | 0.88 | MEN1 (0.74) | MEN1KMT2AMIFPPARGPPARD | |
| SCHEMBL4100021 | 0.86 | MEN1 (0.74) | MEN1KMT2APPARGPPARDPPARA | |
| SCHEMBL7450127 | 0.85 | MEN1 (0.80) | MEN1KMT2AMIFMAPT | |
| SCHEMBL27181090 | 0.82 | MEN1 (0.59) | MEN1KMT2AMAPTPGR | |
| SCHEMBL30926863 | 0.82 | MEN1 (0.59) | MEN1KMT2AMAPTPGR | |
| SCHEMBL4105084 | 0.81 | MEN1 (0.84) | MEN1KMT2APPARGPPARDPPARA | |
| SCHEMBL7448446 | 0.80 | MEN1 (0.72) | MEN1KMT2AMIFMAPT | |
| SCHEMBL30926873 | 0.80 | MEN1 (0.60) | MEN1KMT2AMAPTTHRB | |
| SCHEMBL27179680 | 0.80 | MEN1 (0.60) | MEN1KMT2AMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-1758571-A1 | CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE | 7TM Pharma A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005115374-A1 | CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE | 7TM PHARMA A/S (DK) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | NR1H2, NR1H3, HRH2 | MEN1 2859/4885KMT2A 2570/4885MIF 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.